您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 联合创始人&首席执行官
所属公司: 辉大(上海)生物科技有限公司
个人简介:
姚璇博士为辉大基因创始人&首席执行官,负责公司战略布局、团队组建、项目推进与体系建设。本科毕业于哈尔滨工业大学,并在中科院神经科学研究所获得神经生物学博士学位,创立辉大前曾担任中科院神经科学研究所副高级研究员。期间专注于新型基因编辑技术、动物模型建立及疾病治疗应用等多个领域的研究开发,在国际高水平期刊发表多项成果并申请多项发明专利。With a doctoral degree of Institute of Neuroscience, Chinese Academy of Sciences, Dr. Xuan Yao once served as Associate Senior Researcher at Institute of Neuroscience, Chinese Academy of Sciences, and has published many of his research achievements on Developmental Cell, Cell Research, Genome Biology and other international high-ranking journals.Before founding HuidaGene, Dr. Yao efficiently constructed knock-in mouse models as well as the world’s first knock-in macaques by optimizing gene editing techniques, innovated CRISPR technology to specifically remove entire chromosomes, opening new avenues for modeling and generating therapies for diseases such as Down Syndrome, and worked out an efficient method for somatic cell knockins and technical solutions for the treatment of monogenic diseases. He has an international frontier vision and gains insights into business transformation in terms of the application of new gene editing techniques in animal modeling and in disease treatment.
发布时间: 2023 - 06 - 26
点击次数: 0
所属职位: 医学副总裁
所属公司: 荣昌生物
个人简介:
医学博士。从事肿瘤领域临床研究近二十年,曾任职于解放军总医院第五医学中心消化肿瘤科副主任,副主任医师,硕士生导师。参与全球多中心临床研究,国内创新药的早期、晚期临床研究三十余项。曾作为信达生物医学科学与战略肿瘤部负责人,领导了信迪利单抗、佩米替尼在消化肿瘤多个适应症的成功获批,以及多个早期分子在中国和海外的临床开发。在BMJ, Lancet Oncology, Science Advance,Clinical Cancer Research等知名期刊发表学术论文二十余篇。目前负责荣昌生物肿瘤产品的全球临床开发。Senior Medical Oncologist with 20 years’ experiences in clinical studies, worked as deputy director of the GI Cancer Department of the Fifth Medical Center of PLA General Hospital. Successfully led the development of Sintilimab (anti-PD-1 antibody, Innovent) in GI cancer, got BLA approval for 1L HCC, 1L ESCC and 1L GC, Pemigetinib approval in greater China as global first FGFR inhibitor. Led early-stage and late-stage development of more than 20 oncology assets covering mAb, BsAb, small molecule and ADC. Published more than 20 peer-reviewed papers in BMJ, Lancet Oncology, Science Advance, Clinical Cancer Research, etc. Responsible for the global development strategy and implementation of Remegen oncology pipeline.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 首席商务官
所属公司: 复星凯特生物科技有限公司
个人简介:
负责公司各项外部合作及复星凯特在中国的首款CAR-T的商业化开发,包括销售、商务运营、市场、BD、和准入。曾任上海复星医药集团战略部总监,参与包括复星凯特合资建立、复星领智在内的各项集团内重大投资合作项目。2008至2015年期间于上海交通大学上海免疫学研究从事肿瘤免疫及自身免疫病研究。He’s the Chief Commerical Officer of Fosun Kite Biotechnology Co., Ltd. In charge of Fosun Kite 's various external cooperation and the commercial development of the company's first CAR-T in China, including sales, commercial operations, marketing, access and BD.He used to be the director of the strategy department of Fosun Pharma, and participated in various major investment cooperation projects within the group, including the establishment of Fosun Kite joint venture and Fosun Lead.From 2008 to 2015, he was engaged in tumor immunity and autoimmune disease research at Shanghai Institute of Immunology, Shanghai Jiao Tong University.
发布时间: 2023 - 06 - 25
点击次数: 0
所属职位: 创始人、董事长兼首席执行官
所属公司: 星奕昂
个人简介:
星奕昂创始人、董事长兼首席执行官王立群博士:中国科学技术大学细胞生物学学士、美国马里兰大学巴尔的摩分校分子生物学博士以及辛辛那提萨维尔大学工商硕士,美国国立健康研究院(NIH)博士后。王立群博士在美国和中国的生物制药领域拥有丰富的专业技术和研发管理经验。在成立星奕昂之前,曾任复星医药副总、首席技术官和美国凯特合资公司复星凯特的总裁。用不到三年时间带领复星凯特完成了奕凯达的技术落地,注册临床和生产,成为获中国药监局批准上市的首个CAR-T产品。王立群博士曾在美国宝洁、百时美施贵宝、阿斯利康以及葛兰素史克中国研发中心的重要管理岗位上任职近20年,参与和主导了多个新药的研发及转化工作。他在西比曼生物科技担任首席运营官期间,全面管理公司运营、细胞治疗产品的生产、药理和临床研究,并兼任干细胞事业部总经理。Richard Liqun Wang Ph. D., MBA.• Founder, Chairman and CEO, Neukio Biotherapeutics• VP & CTO, Fosun Pharma• Founding CEO of Fosun Kite Biotech, completed tech transfer, registration trial and market authorization application for Yescarta in China (the first CAR-T product) in less than three years• COO of CBMG (Cellular Biomedical Group), managed production and clinical trials of stem cell and CAR-T therapies• Head of Operations, GSK R&D Center in China• Director of Alliance, Externalization and Portfolio Management, AstraZeneca Innovation Center China• Associate Director, Discovery Portfolio and Project Management, Bristol-Myers Squibb USA• Group Leader & Principal Scientist, Procter & Gamble Pharmaceuticals, USARichard received B.S degree in Cell Biology from the University of Science & Technology of China, Ph.D. in Molecular Biology from the University of Maryland, Baltimore and MBA from Xavier University, in Cincinnati. He obtained postdoctoral training at the National Institutes of Health, USA.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务